Business
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including patients treated with GLP-1 therapies.
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to GLP-1 weight-loss therapies","length":173,"tagName":"p"},{"type":"text","content":"REHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including patients treated with GLP-1 therapies.","length":452,"tagName":"p"},{"type":"image","alt":"CollPlant’s Photocurable dermal filler (CollPlant)","displaySize":"","headline":null,"caption":"CollPlant’s Photocurable dermal filler (CollPlant)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":265,"url":"https://media.zenfs.com/en/prnewswire.com/d8ad2b4ff51f92c2372469f6cbfb9cfd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xa71i1JWeDNQDvleFI7nDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d8ad2b4ff51f92c2372469f6cbfb9cfd","width":400,"height":265}},"href":"https://mma.prnewswire.com/media/2904647/CollPlant_Photo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The expanding use of GLP-1 therapies for metabolic health and weight management has created a growing population experiencing loss of facial fat, skin laxity, and structural deflation - commonly referred to in the medical community as weight-loss-related facial volume depletion.","length":279,"tagName":"p"},{"type":"text","content":"CollPlant's photocurable dermal filler is designed to restore volume while providing a supportive regenerative matrix that integrates with surrounding tissue.","length":162,"tagName":"p"},{"type":"text","content":""Rapid weight loss can lead to significant facial volume depletion and skin quality changes," said Yehiel Tal, Chief Executive Officer of CollPlant. "GLP-1 therapies are creating a new category of aesthetic indications. CollPlant's photocurable filler technology was designed for structural tissue restoration - making it particularly relevant for patients experiencing r...